Manal El-Hamamsy^*, Hesham Elwakil^†, Amr S. Saad^†, May A. Shawki^*

Oncology Research, Vol.24, No.6, pp. 521-528, 2016, DOI:10.3727/096504016X14719078133528

Abstract Statins have been reported to have a potential radiosensitizing effect that has not been evaluated in clinical trials. The aim of this study was to evaluate the efficacy and safety of simvastatin in addition to whole-brain radiation therapy (WBRT) in patients with brain metastases (BM). A prospective randomized, controlled, open-label pilot study was conducted on 50 Egyptian patients with BM who were randomly assigned to receive 30-Gy WBRT (control group: 25 patients) or 30 Gy WBRT+ simvastatin 80 mg/day for the WBRT period (simvastatin group: 25 patients). The primary outcome was radiological response at 4… More >

BEHROOZ JOHARI^1,2,#,*, MILAD PARVINZAD LEILAN^1,#, MAHMOUD GHARBAVI³, YOUSEF MORTAZAVI¹, ALI SHARAFI², HAMED REZAEEJAM⁴

Oncology Research, Vol.32, No.2, pp. 309-323, 2024, DOI:10.32604/or.2023.043576

Abstract The Myc gene is the essential oncogene in triple-negative breast cancer (TNBC). This study investigates the synergistic effects of combining Myc decoy oligodeoxynucleotides-encapsulated niosomes-selenium hybrid nanocarriers with X-irradiation exposure on the MDA-MB-468 cell line. Decoy and scramble ODNs for Myc transcription factor were designed and synthesized based on promoter sequences of the Bcl2 gene. The nanocarriers were synthesized by loading Myc ODNs and selenium into chitosan (Chi-Se-DEC), which was then encapsulated in niosome-nanocarriers (NISM@Chi-Se-DEC). FT-IR, DLS, FESEM, and hemolysis tests were applied to confirm its characterization and physicochemical properties. Moreover, cellular uptake, cellular toxicity, apoptosis, cell More > Graphic Abstract

Heming Lu^*†1, Yuying Wu^‡1, Xu Liu^†, Huixian Huang^†, Hailan Jiang^†, Chaohua Zhu^†, Yuping Man^§, Zhaohong Chen^†, Xianfeng Long^†, Qiang Pang^†, Luxing Peng^†, Xianglong Li^†, Junzhao Gu^†, Shan Deng^†, Ligang Xing^*

Oncology Research, Vol.28, No.9, pp. 929-944, 2020, DOI:10.3727/096504021X16318716607908

Abstract This phase II randomized clinical trial aimed to assess the efficacy and toxicity of Endostar, an antiangiogenesis inhibitor, combined with concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC). Patients with LACC were randomly assigned to either CCRT plus Endostar (CCRT+E arm) or CCRT alone (CCRT arm). All patients received pelvic intensity-modulated radiation therapy (IMRT) and brachytherapy. Weekly cisplatin was administered concurrently with IMRT. Patients in the CCRT+E arm also received concurrent Endostar every 3 weeks for two cycles. The primary endpoint was progression-free survival (PFS) and acute toxicities. The exploratory endpoint was the impact… More >